The efficacy of rotigotine [UCB] versus pramipexole in patients with idiopathic Restless Legs Syndrome (Willis-Ekbom Disease).

Trial Profile

The efficacy of rotigotine [UCB] versus pramipexole in patients with idiopathic Restless Legs Syndrome (Willis-Ekbom Disease).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2014

At a glance

  • Drugs Rotigotine (Primary) ; Pramipexole
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 May 2014 New trial record
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top